Medline Inc. MDLN
Medline Inc. (MDLN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $28.4B at a 4.1% net margin.
Beneish M-score: -2.44 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-12 | JP Morgan | Overweight (main) |
| 2026-08-11 | Tigress Financial | Buy (main) |
| 2026-08-11 | Wells Fargo | Equal-Weight (main) |
| 2026-08-10 | TD Cowen | Buy (main) |
| 2026-08-06 | RBC Capital | Outperform (main) |
| 2026-08-06 | Truist Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.213 |
| Retained earnings / assets | 0.0 |
| EBIT / assets | 0.057 |
| Equity / liabilities | 1.005 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
| SOLV | Solventum Corp | 6/9 | 2.34 | 8.9 | +0.9% |
About Medline Inc.
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
FAQ
Is MDLN financially healthy?
Medline Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MDLN pay a dividend?
No, Medline Inc. does not currently pay a dividend.
How profitable is MDLN?
In FY2025, Medline Inc. had a net margin of 4.1% and a return on equity of 6.0%.
What is MDLN's P/E ratio?
Medline Inc.'s trailing price-to-earnings (P/E) ratio is about 44.1×, based on its latest annual earnings.
What is the analyst price target for MDLN?
The average Wall-Street price target for Medline Inc. is $45.27, about 27.5% above the recent price, from 26 analysts (consensus: buy).
Is MDLN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Medline Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 44.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.